325 related articles for article (PubMed ID: 12703164)
1. [Current treatment of tuberculosis].
García Ramos R; Lado Lado FL; Túnez Bastida V; Pérez del Molino Bernal ML; Cabarcos Ortiz de Barrón A
An Med Interna; 2003 Feb; 20(2):91-100. PubMed ID: 12703164
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Managing TB in the 21st century: existing and novel drug therapies.
Guy ES; Mallampalli A
Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
[TBL] [Abstract][Full Text] [Related]
4. Treatment of tuberculosis in children.
Cruz AT; Starke JR
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):939-57. PubMed ID: 19053906
[TBL] [Abstract][Full Text] [Related]
5. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases.
Shin S; Guerra D; Rich M; Seung KJ; Mukherjee J; Joseph K; Hurtado R; Alcantara F; Bayona J; Bonilla C; Farmer P; Furin J
Clin Infect Dis; 2003 Apr; 36(8):996-1003. PubMed ID: 12684912
[TBL] [Abstract][Full Text] [Related]
6. Approaches to improving adherence to antituberculosis therapy--South Carolina and New York, 1986-1991.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1993 Feb; 42(4):74-5, 81. PubMed ID: 8429808
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents.
Drobac PC; del Castillo H; Sweetland A; Anca G; Joseph JK; Furin J; Shin S
Clin Infect Dis; 2005 Jun; 40(11):1689-92. PubMed ID: 15889370
[TBL] [Abstract][Full Text] [Related]
8. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005.
Pozniak AL; Miller RF; Lipman MC; Freedman AR; Ormerod LP; Johnson MA; Collins S; Lucas SB;
HIV Med; 2005 Jul; 6 Suppl 2():62-83. PubMed ID: 16011537
[No Abstract] [Full Text] [Related]
9. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
10. [Tuberculosis--current therapeutic concepts].
Grünhage F; Sauerbruch T; Spengler U
Dtsch Med Wochenschr; 2005 Jan; 130(4):159-64. PubMed ID: 15662583
[No Abstract] [Full Text] [Related]
11. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.
Cox HS; Niemann S; Ismailov G; Doshetov D; Orozco JD; Blok L; Rüsch-Gerdes S; Kebede Y
Clin Infect Dis; 2007 Jun; 44(11):1421-7. PubMed ID: 17479936
[TBL] [Abstract][Full Text] [Related]
12. [Reform of Japan's NTP and its technical perspectives].
Mori T
Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
[TBL] [Abstract][Full Text] [Related]
13. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2006 Mar; 55(11):301-5. PubMed ID: 16557213
[TBL] [Abstract][Full Text] [Related]
14. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA
Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897
[TBL] [Abstract][Full Text] [Related]
15. Are second-line drugs necessary to control multidrug-resistant tuberculosis?
Nardell EA; Mitnick CD
J Infect Dis; 2006 Nov; 194(9):1194-6. PubMed ID: 17041843
[No Abstract] [Full Text] [Related]
16. Beyond DOtS: avenues ahead in the management of tuberculosis.
Chaudhury RR; Thatte U
Natl Med J India; 2003; 16(6):321-7. PubMed ID: 14765625
[TBL] [Abstract][Full Text] [Related]
17. Treatment of extensively drug-resistant tuberculosis and role of the pharmacist.
Mitrzyk BM
Pharmacotherapy; 2008 Oct; 28(10):1243-54. PubMed ID: 18823220
[TBL] [Abstract][Full Text] [Related]
18. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
20. Current concepts in the management and prevention of tuberculosis in adults.
Fox CW; George RB
J La State Med Soc; 1992 Aug; 144(8):363-8. PubMed ID: 1453094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
